Comparing the current results to its competitors, Pharming Group N V reported Revenue increase in the 4 quarter 2025 by 26.56 % year on year. The sales growth was above Pharming Group N V 's competitors' average revenue growth of 3.14 %, achieved in the same quarter.
Pharming Group N V 's Comment on Competition and Industry Peers
RUCONEST® competes with several approved products in the U.S. for the treatment of Hereditary Angioedema (HAE) attacks. Additional treatments and potential gene therapies for HAE are currently in development. The company may face challenges in maintaining sufficient market penetration and sales levels of RUCONEST® to remain profitable. Joenja® is a recently approved drug in the U.S., the U.K., Japan, Australia, and Israel, which may encounter issues related to safety, efficacy, and regulatory acceptance. The company could also be affected if competitors obtain orphan drug exclusivity, potentially delaying the approval of competing products.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of innovative drugs. Their business model revolves around identifying potential drug targets, conducting research and preclinical studies to validate these targets, and subsequently developing drugs through clinical trials for various therapeutic areas. They also collaborate with pharmaceutical companies for joint development and commercialization efforts, aiming to bring these drugs to market and improve patient outcomes.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Sources:
Pharming Group N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pharming Group N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
